> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Latest Federal Register Notices
- URL: https://www.fdaweb.com/latest-federal-register-notices-147/
- Published: 2017-09-04T12:00:00.000Z
- Updated: 2026-09-14T22:46:14.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5139547

[**Nizoral Not Withdrawn Due to Safety/Effectiveness: FDA**](https://www.fdaweb.com/nizoral-not-withdrawn-due-to-safety-effectiveness-fda/)  
*Federal Register* notice: FDA determines that Janssen Research & Development“ Nizoral (ketoconazole) tablets, 200 milligrams (mg), were not withdrawn from sale for reasons of safety or effectiveness. 09/01/2017

[**Guide on Medical Device Panel Meetings**](https://www.fdaweb.com/guide-on-medical-device-panel-meetings/)  
*Federal Register* notice: FDA announces the availability of a guidance entitled “Procedures for Meetings of the Medical Devices Advisory Committee.” 09/01/2017

[**FDA Ending Support of Earlier Data Tabulation Model**](https://www.fdaweb.com/fda-ending-support-of-earlier-data-tabulation-model/)  
*Federal Register* notice: FDA announces the end of support for Version 1.2 of Clinical Data Interchange Standards Consortium Study Data Tabulation Model (SDTM) and an update to the FDA Data Standards Catalog. 09/01/2017

[**FDA Updates MedDra Medical Dictionary Recognition**](https://www.fdaweb.com/fda-updates-meddra-medical-dictionary-recognition/)  
*Federal Register* notice: FDA announces support for the most current version of the Medical Dictionary for Regulatory Activities, and it ends support for previous versions. 08/31/2017

[**Cenestin Not Withdrawn Over Safety/Effectiveness: FDA**](https://www.fdaweb.com/cenestin-not-withdrawn-over-safety-effectiveness-fda/)  
*Federal Register* notice: FDA determines that Teva’s Cenestin (estrogens, conjugated synthetic A) tablets, 0.3 milligrams (mg), 0.45 mg, 0.625 mg, 0.9 mg, and 1.25 mg, were not withdrawn from sale for reasons of safety or effectiveness. 08/31/2017

[**Draft Guide on Generic Digoxin Tablets**](https://www.fdaweb.com/draft-guide-on-generic-digoxin-tablets/)  
*Federal Register* notice: FDA makes available a draft revised guidance for industry on generic digoxin tablets. 08/30/2017

[**FDA Withdraws Approval of Upsher-Smith’s Propranolol HCl**](https://www.fdaweb.com/fda-withdraws-approval-of-upsher-smiths-propranolol-hcl/)  
*Federal Register* notice: FDA announces that it is withdrawing approval of an Upsher-Smith Laboratories ANDA for propranolol hydrochloride extended-release capsules due to concerns about the validity of bioequivalence data. 08/30/2017

[**Device User Fee Rates for FY 2018**](https://www.fdaweb.com/device-user-fee-rates-for-fy-2018/)  
*Federal Register* notice: FDA announces medical device user fee rates and payment procedures for fiscal year 2018\. 08/29/2017